Monitor for topline data from the SUNRISE-PD and ADDRESS-LC trials expected mid-2026, which could be material catalysts. The KOL event is a credibility-building exercise but does not change near-term fundamentals.
Price Chart
Executive Summary
BioVie announced a virtual KOL event on May 7, 2026, featuring Dr. Suzanne de la Monte to discuss the mechanism of action of its investigational drug bezisterim (NE3107) in Parkinson’s disease. The event will include updates on the ongoing Phase 2 SUNRISE-PD trial and other studies in Long COVID and Alzheimer’s, with topline data expected mid-2026. While no new clinical results were released, the event aims to bolster scientific credibility ahead of data readouts.
Key Facts
- BioVie will host a virtual key opinion leader (KOL) event on May 7, 2026, at 2:00 PM ET.
- Dr. Suzanne de la Monte, a leading expert on brain insulin resistance and 'Type 3 Diabetes,' will participate.
- The event will cover bezisterim's mechanism of action and updates on the SUNRISE-PD Phase 2 trial in Parkinson’s, the ADDRESS-LC trial in Long COVID, and Alzheimer’s studies.
- Topline data from SUNRISE-PD and ADDRESS-LC trials are expected in mid-2026.
- Bezisterim is an oral small molecule targeting neuroinflammation and insulin resistance, with potential applications in Parkinson’s, Alzheimer’s, and Long COVID.
Financial Impact
No immediate financial impact — no new revenue, earnings, or funding disclosed.
Risk Factors
- Clinical trial results may not meet expectations, particularly in larger or later-stage studies.
- Company is in early development stage with no approved products; dependent on trial outcomes and future financing.
- Forward-looking statements highlight risks related to capital raising, regulatory approval, and clinical development uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281541 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $1.37 | awaiting T+20 | — | $1.33 (−2.92%) |
Sep 15, 2026 5w ago | Press Release | $1.75 $1.20 | ▼ −31.43% | ▼ −34.41% | $1.33 (−24.00%) |
Aug 14, 2026 10w ago | S-1/A | $1.17 $1.75 | ▼ −49.57% | ▼ −51.55% | $1.33 (−13.68%) |
Aug 6, 2026 11w ago | S-1/A | $1.35 $2.03 | ▼ −50.37% | ▼ −49.77% | $1.33 (+1.48%) |
Aug 6, 2026 11w ago | 8-K | $1.35 $2.03 | ▲ +50.37% | ▲ +49.77% | $1.33 (−1.48%) |
Jul 31, 2026 12w ago | S-1/A | $1.62 $2.28 | ▼ −40.74% | ▼ −39.50% | $1.33 (+17.90%) |
Jun 30, 2026 17w ago | EFFECT | $1.94 $1.37 | ▲ +29.38% | ▲ +28.35% | $1.33 (+31.44%) |
Apr 27, 2026 26w ago | Press Release | $1.59 $1.44 | ▼ −9.43% | ▼ −14.39% | $1.33 (−16.35%) |
Apr 14, 2026 27w ago | Press Release | $1.46 $1.35 | ▼ −7.53% | ▼ −13.83% | $1.33 (−8.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers